Aytu Bioscience Stock Performance
| AYTU Stock | USD 2.72 0.02 0.74% |
On a scale of 0 to 100, Aytu BioScience holds a performance score of 10. The firm shows a Beta (market volatility) of 0.57, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Aytu BioScience's returns are expected to increase less than the market. However, during the bear market, the loss of holding Aytu BioScience is expected to be smaller as well. Please check Aytu BioScience's potential upside, as well as the relationship between the accumulation distribution and period momentum indicator , to make a quick decision on whether Aytu BioScience's price patterns will revert.
Risk-Adjusted Performance
Fair
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Aytu BioScience are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak basic indicators, Aytu BioScience unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 20 M | |
| Total Cashflows From Investing Activities | -2.6 M |
Aytu BioScience Relative Risk vs. Return Landscape
If you would invest 217.00 in Aytu BioScience on October 28, 2025 and sell it today you would earn a total of 55.00 from holding Aytu BioScience or generate 25.35% return on investment over 90 days. Aytu BioScience is currently generating 0.42% in daily expected returns and assumes 3.1508% risk (volatility on return distribution) over the 90 days horizon. In different words, 28% of stocks are less volatile than Aytu, and 92% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Aytu BioScience Target Price Odds to finish over Current Price
The tendency of Aytu Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 2.72 | 90 days | 2.72 | about 9.12 |
Based on a normal probability distribution, the odds of Aytu BioScience to move above the current price in 90 days from now is about 9.12 (This Aytu BioScience probability density function shows the probability of Aytu Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Aytu BioScience has a beta of 0.57. This suggests as returns on the market go up, Aytu BioScience average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Aytu BioScience will be expected to be much smaller as well. Additionally Aytu BioScience has an alpha of 0.3697, implying that it can generate a 0.37 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Aytu BioScience Price Density |
| Price |
Predictive Modules for Aytu BioScience
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Aytu BioScience. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Aytu BioScience's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Aytu BioScience Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Aytu BioScience is not an exception. The market had few large corrections towards the Aytu BioScience's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Aytu BioScience, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Aytu BioScience within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.37 | |
β | Beta against Dow Jones | 0.57 | |
σ | Overall volatility | 0.27 | |
Ir | Information ratio | 0.11 |
Aytu BioScience Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Aytu BioScience for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Aytu BioScience can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Aytu BioScience had very high historical volatility over the last 90 days | |
| Aytu BioScience has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 66.38 M. Net Loss for the year was (13.56 M) with profit before overhead, payroll, taxes, and interest of 43.03 M. | |
| Aytu BioScience currently holds about 23.81 M in cash with (1.94 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.38. |
Aytu BioScience Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Aytu Stock often depends not only on the future outlook of the current and potential Aytu BioScience's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Aytu BioScience's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 6.3 M | |
| Cash And Short Term Investments | 31 M |
Aytu BioScience Fundamentals Growth
Aytu Stock prices reflect investors' perceptions of the future prospects and financial health of Aytu BioScience, and Aytu BioScience fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Aytu Stock performance.
| Return On Equity | -0.5 | |||
| Return On Asset | 0.0061 | |||
| Profit Margin | (0.21) % | |||
| Operating Margin | (0.11) % | |||
| Current Valuation | 22.06 M | |||
| Shares Outstanding | 10.19 M | |||
| Price To Earning | (0.77) X | |||
| Price To Book | 1.19 X | |||
| Price To Sales | 0.43 X | |||
| Revenue | 66.38 M | |||
| EBITDA | (4.67 M) | |||
| Cash And Equivalents | 23.81 M | |||
| Cash Per Share | 0.38 X | |||
| Total Debt | 22.94 M | |||
| Debt To Equity | 0.47 % | |||
| Book Value Per Share | 2.34 X | |||
| Cash Flow From Operations | (1.94 M) | |||
| Earnings Per Share | (2.23) X | |||
| Total Asset | 124.18 M | |||
| Retained Earnings | (333.54 M) | |||
| Current Asset | 6.36 M | |||
| Current Liabilities | 8.73 M | |||
About Aytu BioScience Performance
Assessing Aytu BioScience's fundamental ratios provides investors with valuable insights into Aytu BioScience's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Aytu BioScience is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. Aytu Biopharma, Inc. was incorporated in 2015 and is headquartered in Englewood, Colorado. Aytu Biopharma operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 164 people.Things to note about Aytu BioScience performance evaluation
Checking the ongoing alerts about Aytu BioScience for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Aytu BioScience help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Aytu BioScience had very high historical volatility over the last 90 days | |
| Aytu BioScience has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 66.38 M. Net Loss for the year was (13.56 M) with profit before overhead, payroll, taxes, and interest of 43.03 M. | |
| Aytu BioScience currently holds about 23.81 M in cash with (1.94 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.38. |
- Analyzing Aytu BioScience's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Aytu BioScience's stock is overvalued or undervalued compared to its peers.
- Examining Aytu BioScience's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Aytu BioScience's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Aytu BioScience's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Aytu BioScience's stock. These opinions can provide insight into Aytu BioScience's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Aytu Stock Analysis
When running Aytu BioScience's price analysis, check to measure Aytu BioScience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aytu BioScience is operating at the current time. Most of Aytu BioScience's value examination focuses on studying past and present price action to predict the probability of Aytu BioScience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aytu BioScience's price. Additionally, you may evaluate how the addition of Aytu BioScience to your portfolios can decrease your overall portfolio volatility.